Retatrutide 2026: Results, Timeline & What It Means for How You’ll Eat
Key takeaways
- Retatrutide is an investigational triple agonist (GLP-1 + GIP + glucagon) – the most powerful weight-loss drug in trials so far.
- TRIUMPH-1: ~24-28% average weight loss at 80 weeks; 45.3% lost at least 30%.
- Not FDA approved; realistic availability is 2027-2028.
- Protein-forward eating protects muscle as appetite drops.
What retatrutide is
Retatrutide (development name LY3437943) is an injectable made by Eli Lilly. Where semaglutide (Ozempic/Wegovy) acts on one appetite pathway and tirzepatide (Mounjaro/Zepbound) acts on two, retatrutide acts on three:
That third pathway is why researchers and patients have paid so much attention: it attacks weight from both sides — eat less and burn somewhat more at rest.
Retatrutide results: what the trials actually showed
TRIUMPH-1 (Phase 3, obesity). 2,339 adults, 80 weeks. On the 12 mg dose, average weight loss landed around 24–28% depending on the statistical analysis used, and 45.3% of patients lost ≥30% of body weight — a threshold rarely reached with medication alone.
Phase 2 (NEJM). The earlier study that started the hype showed about 24.2% weight loss at 48 weeks on 12 mg, with weight still trending down when the trial ended.
Diabetes data (TRANSCEND-T2D-1). In people with type 2 diabetes — who typically lose less — retatrutide 12 mg produced about 16.8% weight loss at 40 weeks.
| Drug | Class | Headline trial | Avg weight loss |
|---|---|---|---|
| Retatrutide (investigational) | Triple agonist | TRIUMPH-1, 80 wk | ~24–28% |
| Tirzepatide (Zepbound/Mounjaro) | Dual agonist | SURMOUNT-1, 72 wk | ~20.9% |
| Semaglutide (Wegovy/Ozempic) | GLP-1 agonist | STEP 1, 68 wk | ~14.9% |
Is retatrutide FDA approved? (No — here’s the real timeline)
The accurate status as of June 2026: retatrutide is not FDA approved and not legally available by prescription. As of mid-2026 Lilly had not yet filed a New Drug Application, but is expected to file before the end of 2026. If filed in Q4 2026, FDA action would realistically come late 2027 to 2028, with a launch shortly after.
Side effects: what the trial data shows
Retatrutide’s side-effect profile looks like the rest of the class — mostly gastrointestinal, mostly during dose escalation, mostly dose-dependent:
- Nausea, diarrhea, vomiting, constipation — worst in the first weeks of each dose step-up, easing at a stable dose.
- Strong appetite loss — so, as with Wegovy and Zepbound, the practical risk shifts from overeating to under-eating protein and losing muscle.
- The glucagon component can modestly raise heart rate and affect glucose handling, which is why trials titrate slowly and monitor closely.
What to eat on retatrutide (the part we actually help with)
Here’s the throughline from every GLP-1 drug to reta: when appetite drops 30–60%, the danger isn’t eating too much — it’s not eating enough of the right things, and losing muscle along with fat. Reta produces the largest appetite reduction in the class, so this matters more here, not less.
- Protein first: roughly 1.2–1.6 g per kg of body weight per day (about 30–50 g per meal). When you can only finish a few bites, those bites should be protein.
- Smaller, more frequent meals during dose escalation, when full plates feel impossible.
- Easy-to-tolerate formats (smoothies, soups, yogurt) on nausea days.
Preparing for the appetite drop? Pre-portioned, macro-labeled meal delivery removes the planning load and guarantees the protein number.
See our tested GLP-1 meal delivery picks →
Or browse Best High-Protein Meal Delivery
Retatrutide FAQ
Is retatrutide FDA approved?
No. As of June 2026 retatrutide is investigational and not available by prescription. Eli Lilly is expected to file an FDA application before the end of 2026, which puts realistic availability in late 2027 to 2028.
Is retatrutide better than Ozempic or Mounjaro?
On weight loss alone the trial data points that way: retatrutide’s roughly 24 to 28 percent beats tirzepatide’s about 21 percent and semaglutide’s about 15 percent across comparable trials. But these are separate studies, not head-to-head, and retatrutide is not approved yet, so Zepbound and Wegovy remain the strongest available options.
How much weight did people lose on retatrutide?
In the pivotal Phase 3 TRIUMPH-1 trial of 2,339 adults, people on the top 12 mg dose lost roughly 24 to 28 percent of body weight over 80 weeks, and 45.3 percent lost at least 30 percent.
Is compounded retatrutide safe?
There is no legitimate compounded retatrutide. Because it is investigational, anything sold under that name is outside the tested, regulated supply chain. We do not recommend it.
What should I eat on retatrutide?
The same approach as any GLP-1 drug, only more so because appetite drops further: prioritize protein at about 1.2 to 1.6 grams per kilogram of body weight per day (30 to 50 grams per meal), eat smaller more frequent meals, and use easy formats like smoothies during dose escalation.
The Retatrutide 2026 series
The nutrition side most drug guides skip
We are a food site, so here is what the drug-only sites leave out: retatrutide works by shrinking appetite, and that creates a real nutritional risk. When you eat far less, you do not just lose fat – you can lose muscle and fall short on protein, fiber, and key vitamins and minerals. The fix is not eating more; it is making every bite count.
The four risks to manage (and the food fix)
| Nutrition risk | Why it happens | The food fix |
|---|---|---|
| Muscle & protein loss | Rapid weight loss plus too little protein – up to a third of lost weight can be lean muscle. | 1.2-1.6 g protein per kg body weight daily; anchor every meal and snack with protein. |
| Low micronutrients | Eating far less total food shrinks intake of iron, B12, calcium, vitamin D, potassium and magnesium. | Nutrient-dense picks: eggs, salmon/sardines, Greek yogurt, leafy greens, beans, nuts and seeds, fortified foods. |
| Constipation | Slowed digestion plus less food and fiber. | Fiber-rich vegetables and fruit you can tolerate; steady fluids; move daily. |
| Dehydration & low energy | Reduced intake and GI fluid losses during dose changes. | Sip fluids and electrolytes through the day; never skip food entirely. |
What to actually eat on retatrutide
- Protein at every meal and snack: eggs, chicken, fish, Greek yogurt, cottage cheese, tofu, beans, or a protein shake. When you can only finish a few bites, make them protein.
- Nutrient-dense, smaller-volume foods: salmon and sardines (omega-3, vitamin D, B12), eggs, dairy, leafy greens, beans and lentils, nuts and seeds, berries.
- Easy formats for nausea days: protein smoothies (protein powder + fruit + spinach), broth-based soups, yogurt.
- Hydration and fiber: water and electrolytes through the day, plus tolerable high-fiber vegetables and fruit to keep things moving.
If your appetite is so low that you are eating very little, a daily multivitamin can backstop the gaps – ask your prescribing clinician. The goal across the board: protect muscle and stay nourished while the medication does its job.
The simplest way to hit these numbers while your appetite is unpredictable is pre-portioned, macro-labeled meal delivery built for exactly this.
See our tested GLP-1 meal delivery picks →
Or browse Best High-Protein Meal Delivery
Sources & references
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine (2023).
- Eli Lilly. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Lilly press release (2026).
- Retatrutide – overview, mechanism, trial history. Wikipedia.
- Retatrutide: what is it and is it FDA approved? Drugs.com.
Related reading
- Best GLP-1 Meal Delivery (Ozempic, Wegovy, Mounjaro, Zepbound)
- GLP-1 Statistics 2026
- Ozempic vs Mounjaro
- What to Eat on Ozempic
Editorial note: figures reflect Eli Lilly topline disclosures and peer-reviewed trial publications available as of June 25, 2026. Retatrutide remains investigational; we will update on NDA filing and FDA action. Not medical advice — consult a licensed clinician.